Patents by Inventor Orit BERHANI

Orit BERHANI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO NKP46 AND CONSTRUCTS THEREOF FOR TREATMENT OF CANCERS AND INFECTIONS
    Publication number: 20230183342
    Abstract: The present invention provides monoclonal antibodies that recognize human NKp46 with high affinity and specificity and do not block NKp46 binding to its natural ligands. The present invention further provides multi-specific antibodies, chimeric antigen receptors (CAR) and uses thereof in treating diseases, particularly malignancies and infections.
    Type: Application
    Filed: April 5, 2021
    Publication date: June 15, 2023
    Inventors: Stipan JONJIC, Ofer MANDELBOIM, Orit BERHANI, Shira KAHALON
  • Anti-NKP46 antibodies, toxin conjugates, and therapeutic use of same
    Patent number: 10716864
    Abstract: An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (CDR) amino acid sequences as set forth in heavy chain ordered N to C terminus: SEQ ID NOs: 4, 6 and 8, and light chain ordered N to C terminus: SEQ ID NOs: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed. Methods of diagnosing, preventing or treating an autoimmune disease or a cancer associated with an expression of NKp46 are also disclosed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 21, 2020
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer Mandelboim, Stipan Jonjic, Orit Berhani, Ariella Glasner
  • ANTI-NKP46 ANTIBODIES, TOXIN CONJUGATES, AND THERAPEUTIC USE OF SAME
    Publication number: 20180207290
    Abstract: An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (CDR) amino acid sequences as set forth in heavy chain ordered N to C terminus: SEQ ID NOs: 4, 6 and 8, and light chain ordered N to C terminus: SEQ ID NOs: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed. Methods of diagnosing, preventing or treating an autoimmune disease or a cancer associated with an expression of NKp46 are also disclosed.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 26, 2018
    Inventors: Ofer MANDELBOIM, Stipan JONJIC, Orit BERHANI, Ariella GLASNER